#Serum Institute of India (SII)

[integrimedical]

https://hiindia.com/sii-invests-in-integrimedical-to-advance-indias-1st-needle-free-tech-20240517103607-11/

SII invests in IntegriMedical to advance India’s 1st needle-free tech

Pune, May 17 (IANS) Serum Institute of India (SII), the world’s largest vaccine manufacturer, on Friday announced a strategic investment in IntegriMedical to advance Needle-Free Injection System (N-FIS) technology.

With the investment, SII will acquire a 20 per cent stake in IntegriMedical. The investment will also accelerate the development and commercialisation of the N-FIS technology, making it more widely accessible to patients in India and worldwide“At SII, we are constantly seeking opportunities to invest in technologies that align with our mission to make healthcare accessible and affordable for people worldwide.

Read more@ https://hiindia.com/sii-invests-in-integrimedical-to-advance-indias-1st-needle-free-tech-20240517103607-11/

[biotichealthcare]

The report published by Kearney in collaboration with the Confederation of Indian Industry titled “Taking India’s life sciences industry to the global stage”, reported that “India’s vaccines industry can grow from $2 billion to $4 billion or even $5 billion”. This has been made possible by a number of factors prominent being the inclusion of vaccines in the product portfolios of several domestic and global pharmaceutical companies. With the pandemic kicking in 2019 end, the entire world came together to build an effective vaccine to fight against the deadly coronavirus.

This report speaks a lot about the Indian biosimilars and vaccines industries and how it is competing globally and scopes for India in the global biosimilars and vaccines industry. It lays down the challenges faced by the Indian pharmaceutical industry and how we can overcome these. It lays down abundant solutions to the challenges faced and how India can ace the Global Pharma sector and command its worthy position both in terms of volume and value.

Indian Vaccine Industry 

The global Pharmaceutical industry has made vaccines their priority. India commands a massive 40% share of the global vaccine industry by volume. India has been playing a pivotal role in combating deadly diseases for years and now the coronavirus pandemic. India is all set to grow to hold a more significant place in the global pharma industry in the coming years. With the introduction of newer and better technologies such as gene therapies, Ai-based informatics, etc has opened boundless opportunities to conduct research and experimentation and develop innovative and effective medications.

India already possesses a strong local pharma industry, fundamentally strong technical capabilities, and rich scientific acumen, that has helped us emerge as an innovational hub of the world. India is the global supplier of drugs and medicines and everybody prefers India for its low-cost manufacturing processes and affordable drugs.

However, Indian Pharmaceutical Industry still lags behind in terms of the value of our market share through being the third-largest volume producer. India faces several challenges that need to be overcome. COVID pandemic offers a great opportunity for India to take a step ahead to bag the top position both in terms of volume and value.

Massive Scope for Global Vaccine supply

There is abundant scope for the export of COVID-19 vaccines globally to countries unable to manufacture vaccines on their own. Moreover, there are several diseases globally that need vaccination, and these infectious diseases amount to more than 70% of the world population. Many countries rely on India for the supply of vaccine doses to combat various infectious diseases. Our own nation has a huge demand for vaccines owing to the huge population count and prevalence of abundant diseases such as diphtheria, tetanus, hepatitis B, measles, mumps, rubella, etc.

India has long been involved in supplying the highly required vaccines to several developing nations at the most affordable prices. So now also the world relied on India for COVID vaccine and India proved to be the biggest exporter of Covid vaccines globally. India itself faced a shortage of vaccines initially due to the heavy burden on the limited resources besides having huge commitments globally. Only two vaccine manufacturers i.e. Serum Institute of India (SII) and Bharat Biotech were operational in the beginning. With limited manufacturing resources, it became difficult to meet both domestic and global vaccine requirements.

This shows the scope for vaccine manufacturing in India provided we develop the required infrastructure and support our pharma medicine developers with the latest and advanced technologies to conduct their research. India requires a favorable statutory and political environment to lead the world with its pharmaceutical products. To be the global leader in terms of value, India needs to be more research-oriented to develop unique formulations to treat health conditions and obtaining Intellectual Property Rights. This is how India can occupy a major pharma share both in terms of volume as well as value.

[starbiopic]

Natasha Poonawalla: The Powerhouse Behind the Poonawalla Empire

The recent buzz about Adar Poonawalla’s acquisition of a 50% stake in Karan Johar’s Dharma Productions has everyone talking, and along with it, the name Natasha Poonawalla is making headlines. While many know her for her bold fashion choices, Natasha is a business leader in her own right, standing as the Executive Director of the Serum Institute of India (SII) and Chairperson of the Vailo…

[decentralvaccine]

Top Drugmaker Buys 50% Stake In Bollywood Studio

India's top vaccine maker has bought a 50% stake in a major Bollywood production company known for making popular films.

Adar Poonawalla’s Serene Production will invest 10bn rupees ($119m; £91.3m) in Karan Johar's Dharma Productions and Dharmatic Entertainment, his company said.

Poonawalla also heads the Serum Institute of India (SII), the world's largest vaccine maker by number of doses, which produced millions of Covid-19 shots for India and many other countries during the pandemic.

Poonawalla’s investment in the entertainment company is a significant move at a time when Bollywood is struggling to overcome lean times since the Covid-19 pandemic shut cinema.

[werindialive]

Why spend so much on Maldives when India has Andaman and Lakshadweep, ask Indian businessmen

The tweets from now suspended Maldives government ministers sparked a fresh controversy as the ministers criticized Indian government, Indians and PM Modi through their social media accounts. The tweets were in response to Prime Minister Modi’s endorsement of Lakshadweep as a tourist destination.

Now, the Indian business leaders have come up with their doubts for why Indian tourists pay so much to visit the island nation when India itself has such beautiful islands including Lakshadweep and Andaman.

Radhika Gupta, MD and CEO, Edelweiss Mutual Fund took to X to state her doubts. “I am obsessed with the potential of Indian tourism…the answer is (1) infrastructure and (2) marketing. The PM’s recent visit has put the spotlight on these destinations. Our hotel brands have shown us time and again that we know how to do luxury like no one else. Let’s take the best of Indian hospitality to build a world class tourism experience,” she posted.

“Our country has so many magnificent tourist destinations, with unimaginable potential; yet to be fully explored. Can any of you guess this Indian tourist haven, just from the pictures I’ve posted?” posted Adar Poonawalla, CEO, Serum Institute of India (SII).

EaseMyTrip also made an announcement stating that it is putting all the flights to Maldives on hold. “In solidarity with our nation, @EasMyTrip has suspended all Maldives flight bookings,” Co-founder and CEO Nishant Pitti posted on his social media account.

Many Indians- including sportsperson, actors and politicians- were outraged by the act of the deputy ministers. Several celebrities and people of status even cancelled their booking to Maldives to condemned the act by Maldives politicians.

For latest news India in Hindi, please subscribe to our newsletter.

[nandedlive]

Dengue vaccine | मोठी बातमी! आता डेंग्यूचा होणार अंत; वर्षभरात येणारं लस, सायरस पूनावाला यांची घोषणा

Dengue vaccine | भारतातील लस किंग सायरस पूनावाला यांनी एक मोठे विधान केले आहे ज्यात त्यांनी म्हटले आहे की ते एका वर्षात डेंग्यूवर बरा करणार आहेत. सिरम इन्स्टिट्यूटचे चेअरमन सायरस पूनावाला यांनी सांगितले की, वर्षभरात आम्ही डेंग्यू उपचार आणि डेंग्यूची लस (Dengue vaccine ) विकसित करू. आफ्रिकन देश आणि भारतात या नवीन लसीची खूप गरज आहे, जिथे लाखो लोकांना या आजाराची लागण होत आहे. Malaria vaccine Covishield च्या यशानंतर, SII जगात प्रथमच मलेरियाची लस लॉन्च करणार आहे. या लसीची आफ्रिकन देशांमध्ये आणि भारताच्या अंतर्गत भागातही नितांत गरज आहे, जिथे लाखो लोकांना या सामग्रीमुळे संसर्ग होत आहे. मोठ्या संख्येने स्त्रियांना संक्रमित करणाऱ्या रोगासाठी एक लस आहे, ही एक लस आहे जी गर्भाशयाला संक्रमित करते. Work started at SII Serum Institute of India एसआयआय सीरम इन्स्टिट्यूट ऑफ इंडियामध्ये काम सुरू सायरस पूनावाला यांनी पत्रकार परिषदेत डेंग्यूसंदर्भात मोठी घोषणा केली. पूनावाला यांनी डेंग्यूच्या लसीची नितांत गरज सांगितली. सिरम इन्स्टिट्यूट डेंग्यूच्या लसीवर दीर्घकाळापासून काम करत आहे. आफ्रिकन देशांव्यतिरिक्त, संपूर्ण आशिया आणि भारतात डेंग्यूमुळे बरेच लोक मरतात. अलीकडेच, सीरम इन्स्टिट्यूटच्या अहवालाने निष्कर्ष काढला की डेंग्यू लसीचा एकच डोस प्रौढांमध्ये सुरक्षित आणि चांगल्या प्रकारे सहन केला जा��ो. सिरम इन्स्टिट्यूटमध्ये डेंग्यूची लस तयार करण्यासाठी सतत चाचणी आणि काम केले ��ात आहे. There will be a vaccine for all four types या चारही प्रकारांसाठी लस असेल सिरम इन्स्टिट्यूट ऑफ इंडियाचे अध्यक्ष सायरस पूनावाला यांनी डेंग्यूची लस वर्षभरात आणण्याची घोषणा केली आहे. यामध्ये डेंग्यूच्या चारही प्रकारांवर उपचार केले जातील. सीरम इन्स्टिट्यूट लवकरच लस बाजारात आणण्याच्या प्रक्रियेकडे पावले टाकू शकते. देशात औषधाच्या प्रसारासाठी जलदगती मंजुरीसाठी विज्ञान आणि तंत्रज्ञान मंत्रालयाकडे अर्ज करण्यासारख्या गोष्टींचा यात समावेश आहे. सीरमने आपल्या तंत्रज्ञानाचा वापर करण्यासाठी यूएस स्थित बायोटेक्नॉलॉजी कंपनी (व्हिस्टेरा) सोबत सहकार्य केले आहे. जागतिक आरोग्य संघटनेच्या (WHO) आकडेवारीनुसार, दरवर्षी 10 ते 40 कोटी डेंग्यू तापाचे रुग्ण आढळतात Read the full article

[ameyawdebrah]

Ghana approves second malaria vaccine

Ghana – one of the first countries to vaccinate against malaria through the pilot malaria vaccine implementation programme (MVIP), supported by Gavi – has granted full national licensure to the R21/Matrix-M™ malaria vaccine, developed by the University of Oxford and manufactured and scaled up by the Serum Institute of India (SII). (more…) “”

[innovationtrends]

Pharmaceutical Fluid Handling Market Size, Growth, Industry Trends, Global Demand, and Forecast 2023-2028

The pharmaceutical fluid handling market is projected to reach US$ 14,209.40 million by 2028; registering at a CAGR of 4.7% from 2022 to 2028, according to a new research study conducted by The Insight Partners.

Equipment Segment Dominated Pharmaceutical Fluid Handling Market in 2021

Increasing drug production and growing adoption of single-use systems in the pharmaceutical industry are the factors that contribute to the pharmaceutical fluid handling market growth. However, high price of failed clinical trials restricts the market growth.

Grab PDF to Know More (Including Table, Full TOC and Figures) @ https://www.theinsightpartners.com/sample/TIPRE00029767/  

Increase in Vaccine Production Provides Opportunity to Pharmaceutical Fluid Handling Market

Vaccines strengthen the immune system of different age groups, providing protection against infectious diseases. In the past few decades, effective immunization has eliminated polio and smallpox, which registered high mortality rates. In recent years, there has been an increase in vaccination demand due to the rising incidences of viral and bacterial infectious diseases. Further, government foundations, hospitals, and pharmaceutical companies are focusing on regular vaccine administration by providing cost-effective immunization globally. This is boosting the demand for vaccine production, which is likely to promote the growth of the pharmaceutical fluid handling market. For instance, the Indian Universal Immunization Programme (UPI) rolled out its pneumococcal conjugate vaccine to 21 lakh children. Additionally, government funding and company investments are stimulating R&D to launch new products. According to World Health Organization, in November 2022, a total of 16 billion vaccine doses, valued at US$ 141 billion, were supplied in 2021, which is approximately three times more than the doses supplied in 2019, i.e., 5.8 billion. The Serum Institute of India (SII) postponed HPV vaccine production for two years due to the focus on the development of COVID-19 vaccines; however, it will begin supplying HPV vaccine to the Government of India by 2023 in small quantities. Thus, an increase in vaccine production is anticipated to create an opportunity for the pharmaceutical fluid handling market during the forecast period.

Based on offering, the global pharmaceutical fluid handling market is segmented into equipment and solutions and services. In 2021, the equipment segment held the largest share of the market, and it is expected to register the highest CAGR during 2022–2028. The equipment & solutions segment is further segmented into metering pumps and capsule equipment (filling/sorting), mixing equipment and valves, thermal processing equipment (coolers/chillers/dryers/heat-exchangers), x-ray inspection systems, tanks for holding liquids and flow control products, filters/filter sets (pre-filters/ sterilizing grade filters/ virus filters), powder handling bags, sterile connectors/disconnectors and membrane filter cartridges, and others. Based on tubing, the market is segmented into TPE, PVC, and silicone.

CIRCOR International Inc, Parker Hannifin Corp, Danaher Corp, Spirax Sarco Engineering plc, Merck KGaA, Rochling SE & Co KG, RAUMEDIC AG, Tef Cap Industries Inc, Fraser Ross Ltd, and Australian Fluid Handling Pty Ltd are the key companies operating in the pharmaceutical fluid handling market.

The report segments the pharmaceutical fluid handling market as follows:

The pharmaceutical fluid handling market is segmented on the basis of offering, tubing, application, usage, end user, and geography. Based on offering, the market is segmented into equipment & solutions and services. Based on tubing, the market is segmented into TPE, PVC, and silicone. Based on application, the market is segmented into fluid handling and management, fluid preparation, integration and automation, aseptic processing, buffer management, and others. Based on usage, the market is segmented into cough syrup, intravenous products, complex APIs, and others. Based on end user, the market is segmented into biotechnology companies, pharmaceutical and medical companies, and others.

In terms of geography, the pharmaceutical fluid handling market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

About US

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Food and Beverages, Consumers and Goods, Chemicals and Materials.

Contact US

Contact Person : Sameer Joshi .

Phone : +1-646-491-9876

E-mail : sales@theinsightpartners.com

[integrimedical]

https://hiindia.com/sii-invests-in-integrimedical-to-advance-indias-1st-needle-free-tech-20240517103607-11/

SII invests in IntegriMedical to advance India’s 1st needle-free tech

Pune, May 17 (IANS) Serum Institute of India (SII), the world’s largest vaccine manufacturer, on Friday announced a strategic investment in IntegriMedical to advance Needle-Free Injection System (N-FIS) technology.

With the investment, SII will acquire a 20 per cent stake in IntegriMedical. The investment will also accelerate the development and commercialisation of the N-FIS technology, making it more widely accessible to patients in India and worldwide“At SII, we are constantly seeking opportunities to invest in technologies that align with our mission to make healthcare accessible and affordable for people worldwide.

Read more@ https://hiindia.com/sii-invests-in-integrimedical-to-advance-indias-1st-needle-free-tech-20240517103607-11/

[news24fr]

Le Serum Institute of India s'emploie à commercialiser ses deux vaccins clés contre le Covid - Covovax et Covishield - en Chine, qui connaît une résurgence de la pandémie. "Il est très important pour le monde de revenir à ses problèmes de chaîne d'approvisionnement et d'investissement… (donc) il vaut mieux pour le monde que la Chine se remette de cela", a déclaré le chef du SII, Adar Ponawala, à NDTV dans une interview exclusive aujourd'hui. "Nous essayons de nous engager avec la Chine et de leur dire de mettre de côté les différences politiques, les problèmes et les appréhensions et de prendre certains des vaccins occidentaux comme rappel", a-t-il déclaré. Interrogé sur la réponse de la Chine, il a déclaré : "Je pense qu'ils décident de la direction qu'ils veulent prendre... J'espère juste qu'ils décideront rapidement d'une manière ou d'une autre". La nouvelle épidémie en Chine qui a commencé l'année dernière a été attribuée à un cocktail de virus par des experts indiens de la santé. Dans une interview avec NDTV l'année dernière, NK Arora, le chef du panel Covid du Centre, a déclaré: "En Chine, ils n'ont jamais été exposés au virus auparavant, et le vaccin qu'ils ont reçu est probablement moins efficace. La plupart d'entre eux ont reçu trois à quatre doses". M. Poonawalla a déclaré à NDTV que Covovax a fait ses preuves et fonctionne bien contre Omicron. Sa réponse est deux ou trois fois supérieure à celle même de Covishield – l'un des deux vaccins introduits pour la première fois en Inde et dans de nombreux autres pays. Le nouveau vaccin, a déclaré M. Poonawalla, coûtera environ 200 à 300 Rs et sera bientôt sur l'application CoWin du Centre. SII, a déclaré M. Poonawalla, a également soumis des données sur son vaccin contre le paludisme à l'Organisation mondiale de la santé. Le vaccin, a-t-il dit, s'est révélé efficace dans plus de 77% des cas et ils prévoient de le déployer d'ici la fin de l'année en Afrique. Le plus grand fabricant de vaccins en Inde, SII travaille également sur un vaccin contre la dengue, qui est en phase 2-3 d'essais cliniques. Le vaccin, à administrer en trois doses, pourra être prêt dans deux ans, a-t-il ajouté.

[starbiopic]

Adar Poonawalla Net Worth: ₹1.07 Lakh Crore Tycoon Buys 50% Stake in Dharma Productions

Adar Poonawalla, CEO of the Serum Institute of India (SII), has acquired 50% ownership of Dharma Productions, the film company led by Karan Johar. Through a ₹1,000 crore investment by his Sirin Productions, Poonawalla now holds an equal stake in Dharma, valued at ₹2,000 crore. This collaboration aims to create diverse content, expanding the reach of Dharma Productions beyond Bollywood films. Who…

[newswireml]

Poonawalla gets Patangrao Kadam award, Maha Dy CM hails SII for vaccine#Poonawalla #Patangrao #Kadam #award #Maha #hails #SII #vaccine

Poonawalla gets Patangrao Kadam award, Maha Dy CM hails SII for vaccine#Poonawalla #Patangrao #Kadam #award #Maha #hails #SII #vaccine

Maharashtra Deputy Chief Minister Devendra Fadnavis on Sunday lauded vaccine manufacturer Serum Institute of India and its CEO Adar Poonwalla for their contribution in the fight against COVID-19. He was speaking at the inauguration of Bharti Super Specialty Hospital at Bharti Vidyapeeth where Poonwalla was conferred with the first Dr Patangrao Kadam Memorial Award. “I am very happy we got the…

[decentralvaccine]

Children In Ivory Coast Receive New Doses Of Malaria Vaccine

—

Children in Ivory Coast received the first doses of a new, relatively cheap malaria vaccine on Monday, a step that has been hailed as a major milestone in the battle against one of the world’s most deadly diseases.

The R21 vaccine, developed by the Jenner Institute at the University of Oxford and the Serum Institute of India (SII), has been sent to several African countries and will also be administered in South Sudan Tuesday, the University of Oxford said in a statement sent to CNN.

[janchowk]

कोवैक्सिन टीका वाले लोगों को यात्रा मंजूरी न मिलने को सरकार ने निराधार बताया

कोवैक्सिन टीका वाले लोगों को यात्रा मंजूरी न मिलने को सरकार ने निराधार बताया

भारत सरकार ने शनिवार को उन रिपोर्टों को खारिज कर दिया, जिसमें दावा किया गया था कि जिन लोगों को कोवैक्सिन का टीका लगाया गया है, वे विदेश यात्रा के लिए योग्य नहीं हो सकते हैं क्योंकि कई देशों ने अभी तक कोवैक्सीन को मंजूरी नहीं दी है। केंद्रीय सूचना एवं प्रसारण मंत्री प्रकाश जावड़ेकर ने कल एक प्रेस वार्ता में कोवैक्सिन टीका लेने वाले लोगों के यात्रा प्रतिबंध के दावे को निराधार बताते हुये कहा कि-…